ArticleSexual medicine2026
Validation of the Turkish version of the ANDROTEST for detecting male hypogonadism in patients with sexual dysfunction.
Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male hypogonadism is an important endocrine cause of sexual dysfunction, yet symptom-based screening tools require cultural and linguistic validation to ensure their reliability across different populations. Aim: To evaluate the diagnostic performance, reliability, and validity of the Turkish version of the ANDROTEST in men presenting with sexual dysfunction. Methods: This prospective observational study included men aged 18-80 years presenting to the andrology outpatient clinic with symptoms of sexual dysfunction between February and November 2025. A control group consisted of age-matched individuals without clinical suspicion of hypogonadism or conditions affecting gonadal function. Participants completed the Turkish versions of Beck Depression Inventory (BDI) and the International Index of Erectile Function (IIEF). The ANDROTEST was translated and culturally adapted using a forward-backward translation process. Diagnostic performance was evaluated using receiver operating characteristic curve analysis, while test-retest reliability was assessed using the intraclass correlation coefficient (ICC). Multivariable logistic regression analysis was performed to identify independent predictors of hypogonadism. Outcomes: The primary outcome was the diagnostic performance of the Turkish ANDROTEST for identifying hypogonadism. Results: A total of 246 participants were included (120 controls and 126 patients with hypogonadism). Hypogonadal patients demonstrated significantly higher body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and BDI, whereas total testosterone, free testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, IIEF scores, and testicular volumes were significantly lower (all Clinical Implications: The Turkish version of the ANDROTEST may serve as a practical screening tool for identifying men at risk of hypogonadism in routine clinical practice. Strengths and Limitations: Strengths include the prospective design and comprehensive evaluation of psychometric and diagnostic performance. Limitations include the single-center design and the case-control structure, which may overestimate diagnostic performance. Conclusion: The Turkish version of the ANDROTEST demonstrated excellent diagnostic performance and strong reliability for identifying male hypogonadism in men with sexual dysfunction, supporting its potential utility as a culturally adapted screening tool in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.